Pediatric heart transplant recipients have been expected to be at higher risk of adverse events from developing COVID-19 infection. COVID-19 RNA PCR and antibody testing has been performed in our cohort of patients since March 15, 2020 and outcomes were reviewed. COVID-19 infection in our population of pediatric heart transplant recipients is common (21%), despite recommendations to avoid contact with others. Asymptomatic COVID-19 infection is common as well (55%). Despite the frequency of infection, COVID-19 is well tolerated in this population (5% admission from home; 0% mortality). A suppressed immune system does not significantly inhibit an antibody response in pediatric heart transplant recipients (>70% antibody seroconversion) and appears to persist, similar to those without transplantation (>90 days). Routine testing for COVID-19 via PCR and antibody testing enhances the ability to detect COVID-19 infection in asymptomatic patients and may help reduce unintended transmission to more susceptible individuals.

预计小儿心脏移植受者因感染 COVID-19 而发生不良事件的风险更高。自 2020 年 3 月 15 日以来，我们对我们的患者队列进行了 COVID-19 RNA PCR 和抗体检测，并对结果进行了审查。尽管建议避免与他人接触，但在我们的儿科心脏移植受者群体中，COVID-19 感染很常见（21%）。无症状的 COVID-19 感染也很常见（55%）。尽管感染频率很高，但该人群对 COVID-19 的耐受性良好（在家住院 5%；死亡率 0%）。受抑制的免疫系统不会显着抑制小儿心脏移植受者的抗体反应（> 70% 抗体血清转换），并且似乎持续存在，类似于未接受移植的受者（> 90 天）。